Literature DB >> 16296775

Nicotine delivery systems.

Saul Shiffman1, Reginald V Fant, August R Buchhalter, Joseph G Gitchell, Jack E Henningfield.   

Abstract

Over the past 20 years, medicinal nicotine has been used to aid smoking cessation, and has led to a significant increase in the number of smokers who successfully quit. This review describes currently available medicinal nicotine products, which include nicotine patch, gum, lozenge, nasal spray, inhaler and sublingual tablet, including their pharmacokinetics and recommended dosing. New developments in nicotine delivery that could further increase cessation rates include high-dose patches, rapid release gum, combined patch and acute forms, and several novel channels for nicotine delivery, such as nicotine drink, straw, lollipop and a pulmonary inhaler. New applications of existing and novel medicinal nicotine products may include relapse prevention, nicotine maintenance, temporary withdrawal management, reduced smoking and gradual quitting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296775     DOI: 10.1517/17425247.2.3.563

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  9 in total

1.  Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender.

Authors:  Sarah E Evans; Melissa Blank; Cynthia Sams; Michael F Weaver; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

2.  The effect of acute exercise on cigarette cravings while using a nicotine lozenge.

Authors:  Amelia Tritter; Lyndsay Fitzgeorge; Harry Prapavessis
Journal:  Psychopharmacology (Berl)       Date:  2015-02-22       Impact factor: 4.530

Review 3.  Comparison of available treatments for tobacco addiction.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

4.  Effects of transdermal nicotine and concurrent smoking on cognitive performance in tobacco-abstinent smokers.

Authors:  Bethea A Kleykamp; Janine M Jennings; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.157

Review 5.  Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell).

Authors:  Bertrand Dautzenberg; Mitchell Nides; Jean-Luc Kienzler; Anne Callens
Journal:  BMC Clin Pharmacol       Date:  2007-10-08

Review 6.  Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

Authors:  August R Buchhalter; Reginald V Fant; Jack E Henningfield
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems.

Authors:  Lion Shahab; Leonie S Brose; Robert West
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

8.  Long-acting Preparations in Substance Abuse Management: A Review and Update.

Authors:  Aditya Hegde; Shubh Mohan Singh; Siddharth Sarkar
Journal:  Indian J Psychol Med       Date:  2013-01

Review 9.  A systematic review of possible serious adverse health effects of nicotine replacement therapy.

Authors:  Peter N Lee; Marc W Fariss
Journal:  Arch Toxicol       Date:  2016-10-03       Impact factor: 5.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.